Corcept Cushing's drug hits mark in Phase III trial
This article was originally published in Scrip
Executive Summary
Corcept Therapeutics reported that top-line results of its Phase III trial of Corlux (mifepristone) demonstrated a statistically significant improvement in glucose intolerance and hypertension in patients with Cushing's syndrome, a rare hormonal disorder caused by prolonged exposure to cortisol.